文献速递神经肿瘤

ABTC-0904:靶向胶质母细胞瘤中的胶质瘤干细胞——Hedgehog通路抑制剂GDC-0449的0/II期研究

ABTC-0904: targeting glioma stem cells in GBM: a phase 0/II study of hedgehog pathway inhibitor GDC-0449.
PubMed 文献 · J Neurooncol · 2022-12-29

ABTC-0904是一项双组、多中心0/II期研究,评估口服Smoothened(SMO)抑制剂GDC-0449在复发胶质母细胞瘤(GBM)切除术患者中的疗效。41例入组,Arm I术前术后均用药,Arm II仅术后用药。GDC-0449耐受良好并到达肿瘤、抑制CD133+神经球形成,但单药临床疗效有限,PFS-6为2.4%。

要点

  • GDC-0449在75%患者血浆浓度达预期治疗范围,治疗耐受良好。
  • Arm I用药后CD133+神经球形成、增殖、自我更新及SHH下游信号显著降低。
  • 两组均无客观缓解,总体PFS-6为2.4%,中位PFS 2.3个月,中位OS 7.8个月。

核心结论

  • GDC-0449耐受良好、到达肿瘤并抑制CD133+神经球形成,但作为单药在复发GBM中临床疗效有限。
  • 作者认为复发GBM的生长和维持并非仅依赖SHH通路,因此靶向SMO可能需要联合方案。

研究设计与样本

  • ABTC-0904为双组、多中心0/II期研究,纳入接受切除术的复发GBM患者。
  • 所有患者(Arm I和Arm II)均接受手术并于术后用药,仅Arm I在术前接受GDC-0449。
  • 主要终点为6个月无进展生存(PFS-6),次要终点包括中位PFS、中位OS、缓解率和毒性。
  • 相关研究包括GDC-0449生物分析及SHH信号、GSC增殖与自我更新的抑制检测。
  • 共41例患者入组。

主要发现

  • GDC-0449血浆药代动力学显示75%患者浓度在预期治疗范围内。
  • 与Arm II(术前未用药)相比,Arm I用药后产CD133+神经球的肿瘤细胞比例、神经球增殖、自我更新及SHh下游信号表达显著降低(分别为p<0.005和p<0.001)。
  • 两组均无客观缓解者。
  • 总体PFS-6为2.4%(95%CI 0.9-11.1%),中位PFS为2.3个月(95%CI 1.9-2.6),中位OS为7.8个月(95%CI 5.4-10.1)。
  • 治疗耐受良好。

关键数值与推荐

  • PFS-6为2.4%(95%CI 0.9-11.1%)。
  • 中位PFS为2.3个月(95%CI 1.9-2.6),中位OS为7.8个月(95%CI 5.4-10.1)。
  • Arm I用药后CD133+神经球形成、增殖、自我更新及SHh下游信号表达较Arm II显著降低(p<0.005;p<0.001)。
  • 75%患者GDC-0449血浆浓度在预期治疗范围内。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Gliomagenesis and resistance of glioblastoma (GBM) are believed to be mediated by glioma stem cells (GSC). Evidence suggests that SHH signaling promotes GSC proliferation and self-renewal. METHODS: ABTC-0904 was a two-arm, multicenter phase 0/II study of GDC-0449, an oral inhibitor of Smoothened (SMO) in patients undergoing resection for recurrent GBM. All patients (Arms I and II) had surgery and received drug post-operatively. Only patients in Arm I received drug prior to surgery. The primary objective was to determine 6-month progression free survival (PFS-6). Secondary endpoints include median PFS (mPFS) and overall survival (mOS), response rate, and toxicity. Correlative studies included bioanalysis of GDC-0449, and inhibition of SHH signaling, GSC proliferation and self-renewal. RESULTS: Forty-one patients were enrolled. Pharmacokinetics of GDC-0449 in plasma demonstrated levels within expected therapeutic range in 75% of patients. The proportion of tumorcells producing CD133+ neurospheres, neurosphere proliferation, self-renewal, and expression of the SHh downstream signaling was significantly decreased in Arm I following GDC-0449 treatment (p < 0.005; p < 0.001 respectively) compared to Arm II (no drug pre-op). Treatment was well tolerated. There were no objective responders in either arm. Overall PFS-6 was 2.4% (95% CI 0.9-11.1%). Median PFS was 2.3 months (95% CI 1.9-2.6) and mOS was 7.8 months (95% CI 5.4-10.1). CONCLUSIONS: GDC-0449 was well tolerated, reached tumor, and inhibited CD133+ neurosphere formation, but had little clinical efficacy as a single agent in rGBM. This suggests growth and maintenance of rGBM is not solely dependent on the SHH pathway thus targeting SMO may require combined approaches.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Sloan AE, Nock CJ, Ye X, et al. ABTC-0904: targeting glioma stem cells in GBM: a phase 0/II study of hedgehog pathway inhibitor GDC-0449. J Neurooncol. 2022. PMID: 36581779. doi:10.1007/s11060-022-04193-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。